Unit 4 summary.pdf
Transcript
Unit 4: Explain in detail the significance of incorporating drugs into various dosage forms: Dosage form The choice of dosage form for drugs is crucial in pharmaceutical formulation, influencing administration, absorption, and therapeutic efficacy, influenced by factors like drug properties, adminis...
Unit 4: Explain in detail the significance of incorporating drugs into various dosage forms: Dosage form The choice of dosage form for drugs is crucial in pharmaceutical formulation, influencing administration, absorption, and therapeutic efficacy, influenced by factors like drug properties, administration route, patient characteristics, and therapeutic goals. Oral dosage forms like tablets, capsules, syrups, and suspensions are preferred due to their convenience and ease of administration. These forms enhance bioavailability and absorption, while liquid dosage forms offer faster absorption. Solid dosage forms are stable and have longer shelf life, while parenteral dosage forms use injections for unstable gastrointestinal tract drugs or rapid action. Targeted drug delivery is possible through creams, ointments, patches, and gels. Oral liquids and dispersible tablets are preferred for paediatric and geriatric patients. Flavouring oral liquids can improve patient acceptance. Extended-release formulations provide controlled and sustained drug release, while flexible dosing allows for individualized therapy. In emergency situations, injectable dosage forms are preferred. 1. Which factor plays a significant role in the choice of dosage form for incorporating drugs? A) Drug's physicochemical properties B) Drug manufacturer's location C) Drug's brand name D) Drug expiration date Correct! The physicochemical properties of the drug, such as solubility, stability, and permeability, are crucial in determining the appropriate dosage form. 2. What is a critical aspect of pharmaceutical formulation related to incorporating drugs into dosage forms? Choices A) Packaging design B) Drug discovery process C) Marketing strategy D) Administration and absorption Correct! Incorporating drugs into various dosage forms significantly impacts the administration, absorption, and therapeutic efficacy of medications. What plays a significant role in determining the intended route of administration for a drug's dosage form? Choices A) Patient's favourite flavour B) Drug production cost C) Therapeutic goals D) Drug colour Correct! The intended route of administration is influenced by factors such as therapeutic goals, patient characteristics, and drug properties. Preformulation Studies: Preformulation studies are crucial in drug development to understand the physical and chemical properties of a drug substance. These studies help select appropriate formulation methods and predict dissolution rates. They also assess the drug's chemical stability under various environmental conditions, such as temperature, humidity, and light. The solubility and dissolution studies help design formulations for specific routes of administration. Compatibility studies assess the drug's compatibility with excipients, processing aids, and packaging materials. Understanding the bulk density (used in determining the amount of powder that can fit in a space) and compressibility is essential for tablet formulation. Flow properties evaluate the drug powder's flow for uniform mixing and precise dosing. The melting point determines the drug's processing methods. Biopharmaceutical considerations guide the selection of dosage forms and administration routes. Analytical methods are developed for accurate quantification during formulation development and quality control. Most drug substances in use today are solid materials, pure chemical compounds of either crystalline or amorphous constitution (Crystalline solids have a repeating pattern of particles, resulting in a definite shape, while amorphous solids have random particles, resulting in irregular shapes). Morphology (colour, taste, size, shape, and special features, like touch, texture, fracture and presence of trichomes) are studied under morphology. Solubility of a drug is crucial for its bioavailability and is determined by kinetic and equilibrium solubility. Kinetic solubility ( used to measure the rate at which a compound dissolves in an aqueous buffer system or biorelevant medium) is determined by dissolving the drug in DMSO (dimethyl sulfoxide) and adding water, then filtering and measuring concentrations using UV or LC/MS techniques. Thermodynamic solubility helps identify polymorphic and amorphous forms of the drug. Other methods of solubility analysis include pKa determination, partition coefficient, drug dissolution, and membrane permeability. Drugs are primarily weakly acidic or basic, resulting in either ionized or un-ionized species based on pH. Un-ionized drug molecules are more lipid-soluble and absorb more effectively than ionized ones. The Henderson-Hasselbach equation estimates ionization of a weak acid or base at a given pH. The pKa of a drug can be determined using UV or visible spectroscopy, potentiometric titration, conductimetry, or dissolution rate methods. The partition coefficient (log P) indicates drug lipophilicity, with higher values indicating increased drug cross-linking. The partition coefficient is defined as the ratio of un-ionized drug distributed between the organic phase ( Corganic ) and aqueous phases (Caqueous) at equilibrium. Ko/w = [Corganic/ C aqueous] 1. What do preformulation studies in drug development help predict? A) Biological half-life B) Metabolism pathways C) Dissolution rates D) Drug-target interactions Correct! preformulation studies help predict dissolution rates, which are crucial for designing appropriate drug formulations. 2. Why are compatibility studies important in drug development? A) To predict the drug's side effects B) To evaluate the drug's solubility C) To assess the drug's compatibility with excipients and packaging materials D) To determine the drug's biological activity Correct! Compatibility studies assess the drug's compatibility with excipients, processing aids, and packaging materials, which is essential for formulation development. 3. What do flow properties evaluate in drug powder? A) Uniform mixing and precise dosing B) Biological half-life D) Chemical reactivity Correct! Flow properties evaluate the drug powder's flow for uniform mixing and precise dosing, which are critical for formulation development. 4. Which method helps identify polymorphic and amorphous forms of a drug based on solubility? A) Partition coefficient determination B) pKa determination C) Thermodynamic solubility D) Drug dissolution analysis Correct! Thermodynamic solubility helps identify polymorphic and amorphous forms of the drug. 5. What does the partition coefficient ( logP ) indicate about a drug? A) pKa determination B) pH level at which the drug is most soluble C) Ksp value for the drug D) Drug lipophilicity, with higher values indicating increased drug cross-linking Correct! The partition coefficient ( logP) indicates drug lipophilicity, with higher values indicating increased drug cross-linking. 6. What does the partition coefficient (log P) indicate about a drug's ability to cross the biological cell membrane? A) The log P value has no correlation with the drug's ability to cross the biological cell membrane B) The lower the log P value, the greater the drug's ability to cross the biological cell membrane C) The log P value directly relates to the drug's solubility in water D) The higher the log P value, the greater the drug's ability to cross the biological cell membrane Correct! The partition coefficient (log P) is defined as the ratio of un-ionized drug distributed between the organic phase and aqueous phases at equilibrium. A higher log P value indicates a greater ability for the drug to cross the biological cell membrane. 7. What property is highly desirable for drug absorption, according to the text? A) Extreme lipophilicity for passive absorption B) An optimal balance between lipophilicity and solubility C) High solubility regardless of lipophilicity D) Low solubility with high lipophilicity Correct! The text emphasizes that an optimal balance between lipophilicity and solubility is highly desirable for drug absorption. This balance ensures effective absorption while addressing issues related to low solubility. Dissolution rate: Dissolution studies are crucial for understanding the rate and extent of absorption of drugs within the human body. The dissolution rate is the speed at which a drug substance dissolves in a medium and is determined by the NoyesNernst equation. Surface area affects the dissolution rate, and the intrinsic dissolution rate (IDR) can be calculated by studying a drug substance's dissolution rate with a constant surface area. Two commonly used apparatuses for determining IDR are the fixed-disk system (USP) and Wood's apparatus. IDR also helps determine thermodynamic parameters associated with crystalline phase transitions. What does the Noyes-Nernst equation describe? A) The solubility of a drug substance in different media B) The dissolution rate of solids in a given medium under fixed hydrodynamic conditions C) The absorption rate of a drug substance in the human body D) The surface area influence on the dissolution rate of a drug substance Correct! The Noyes-Nernst equation describes the dissolution rate of solids in a given medium under fixed hydrodynamic conditions. What does the intrinsic dissolution rate (IDR) depend on? A) Temperature and pressure B) Solubility only C) Both solubility and surface area D) Surface area only Correct! The intrinsic dissolution rate (IDR) depends on both solubility and surface area, as per the modified Noyes-Whitney equation. Stability testing aids drug product development, including processing, storage, and absorption in the gastrointestinal mucosa. It includes solid state, solution phase, physical, and photostability studies, revealing potential degradation routes and products. Formulation studies Drug formulation is the process of combining inactive substances with active pharmaceutical ingredients (API) to create a safe and effective drug product for patients. It involves assessing stability, efficacy, and processability in the formulation development phase. Most new drugs are marketed as tablets and capsules, with some as injections. Other dosage forms depend on the success of tablets, capsules, and injections. Preclinical and clinical studies evaluate the product's safety and efficacy, and it must be manufactured in accordance with good manufacturing practices (GMPs). What is drug formulation? A) The process of manufacturing drugs in accordance with GMPs B) The process of conducting preclinical and clinical studies C) The process of identifying pharmaceutical excipients D) The process of determining the best way to deliver an active ingredient Correct! Drug formulation involves combining different inactive substances with the active pharmaceutical ingredient to produce an end-product for patients What is the next step after developing the formulation and dosage form? A) Assessing different drug product concepts B) Manufacturing the drug in a clean and sterile environment C) Evaluating the safety and efficacy of the drug product in humans D) Conducting preclinical and clinical studies Correct! After developing the formulation and dosage form, the next step is to conduct preclinical and clinical studies to evaluate the safety and efficacy of the drug product. What are pharmaceutical excipients classified according to? A) Function they perform B) Color and appearance C) Chemical structure D) Cost-effectiveness Correct! Pharmaceutical excipients are classified according to the function they perform in drug formulation. Manufacturing Methods for Oral Solid Dosage Form Tablet formulation methods include direct compression and granulation, with dosage forms determined by manufacturing techniques like feeding, blending, milling, granulation, drying, compression/encapsulation, and coating. Direct compression (DC) is a process that compresses tablets from powder blends of API with excipient and lubricant, reducing the number of unit operations required and reducing energy consumption. It is economical, requires only three operations, and is ideal for moisture or heat sensitive APIs. However, DC cannot be used for all APIs, and formulations should accommodate these limitations. Granulation, a technique of particle enlargement by agglomeration, is used to increase flowability and decrease dustability. It improves the powder blend's flow properties, narrows particle size distribution, improves compactability, increases density, prevents segregation, increases uniformity and homogeneity, and controls drug release rate. Granulation can be classified into dry and wet granulation. Dry granulation is a cost-effective and flexible method for pharmaceutical APIs sensitive to solvents, heat, and moisture. It involves mechanical compression or compaction of powder mixture with binder to facilitate particle agglomeration. The process involves milling, blending, compression, and mixing to produce desired particle sizes. Wet granulation is the most used method for tablet manufacturing, achieved by massing APIs and excipients with granulation liquid, sizing, and drying. It improves bulk density, flowability, mixing homogeneity, color distribution, and dissolution of hydrophobic drugs. However, it requires expensive equipment, space, time, and energy, and is not suitable for moisture and heat-sensitive APIs. Feeders are also needed for continuous manufacturing. Wet granulation involves various methods to produce granules, with high shear granulation and fluid bed granulation being more common. High shear granulation involves mixing, spraying binder liquid on a powder bed, attrition, breakage, and drying. It has advantages like short granulation time, handling viscous materials, and predictable end points. However, it can lead to mechanical degradation and is not suitable for thermo-labile powders. Fluidized bed granulation involves fluidizing a powder mix in heated air, spraying liquid binder, and drying. Which process is involved in direct compression for tablet manufacturing? A) Lyophilization of APIs and excipients B) Milling of APIs and excipients C) Coating of APIs and excipients D) Granulation of APIs and excipients Correct! Direct compression involves the milling of APIs and excipients, not granulation, coating, or lyophilization. What characteristic makes direct compression ideal for moisture or heat sensitive APIs? A) pKa value close to pH 7 B) IDR value above 50 C) Elimination of moisture and heat treatment D) logP value close to 1 Correct! Direct compression is ideal for moisture or heat sensitive APIs due to the elimination of moisture and heat treatment, not due to specific logP,, pKa values, or intrinsic dissolution rate (IDR) values. What is a primary disadvantage of wet granulation compared to dry granulation? A) Suitability for heat-sensitive APIs B) Prevention of segregation of APIs C) Improved flowability of powder blends D) Time-consuming and complex process Correct! Wet granulation is a time-consuming and complex process, especially during the drying phase. What is a disadvantage of fluidized bed granulation? A) Over wetting can lead to larger granules B) Not suitable for thermo-labile powders C) Mechanical degradation (fragile particles) D) Problems with reproducibility Correct! A disadvantage of fluidized bed granulation is problems with reproducibility, as stated in the text. What affects fluidized bed granulation process? A) Fluidising air flow rate/gas velocity B) Impeller & chopper speed C) Load of the vessel D) Granulating solution addition rate and method Correct! The fluidising air flow rate/gas velocity affects fluidized bed granulation process, as stated in the text. Routes of administration: The absorption, distribution, and elimination of a drug can be monitored by measuring its concentration in the blood. The initial phase involves delivery in dosage form, followed by absorption and distribution before elimination. Key data points include the maximum concentration (Cmax), time after administration, absorption rate (Tmax), and AUC. The duration of action and effectiveness can be assessed using minimum effective concentration (MEC) and maximum tolerated concentration (MTC). Drugs are absorbed from the GI Tract and pass through the portal vein before being bioavailable. Oral dosage forms are typically solids or liquids. Dissolution rate depends on solubility at the gastric pH, drug molecular structure, and particle size. Smaller particles dissolve faster, making the drug available for absorption. Most solid dosage forms disintegrate on contact with gastric fluids to reduce particle size. Solute = substance that it being dissolved. Solution = when one substance dissolves into another which forms a solution. API = active pharmaceutical ingredient Excipients = inert additives such as binders, lubricants and colours etc. EC= enteric coated GR= gastro resistant The concentration of a drug in a solution is crucial for its dissolution rate, which can be sink or non-sink. Sink dissolution occurs when the solute is removed faster than it passes into the solution, while non-sink dissolution occurs when the dosage form dissolves quickly, affecting the dissolution rate. Solid oral dosage forms include tablets, capsules, and modified solid oral dosage forms. Tablets are combined with excipients and are available in various shapes, sizes, and colours. Modified release forms provide targeted drug delivery or sustained or controlled release of the active pharmaceutical ingredient (API). Enteric coated or gastro resistant tablets, also known as delayed release dosage forms, have a coating that is insoluble in stomach acid conditions, protecting the drug from degrading in the stomach. EC and GR coated tablets dissolve and release drugs under intestine pH conditions, making them unsuitable for use with antacids. Tablets can be coated or formulated to prolong release, reducing dosing frequency. Drug release can be delayed, repeated, prolonged, sustained, extended, or controlled. Delayed release indicates a delayed release, while repeated action indicates a rapid release. Sustained release provides a therapeutic dose immediately, while extended release maintains plasma concentrations for extended periods. Controlled release maintains constant plasma concentrations over time. The MHRA recommends using suffixes for prolonged release preparations, such as CR (controlled release), LA (long acting), PR (prolonged release), SA (sustained action), SR (sustained release), and XL (once daily dosing). Tablets or dosage forms modified with active coatings should not be broken, crushed, or chewed, as this can destroy the coating's integrity. XL formulations contain a higher amount of the API than standard dosage forms, so breaking or damaging the coating can lead to dose dumping. What is the key factor influencing dissolution rate in oral dosage forms? A) Type of inert additives such as binders and lubricants B) Drug molecular weight and color of excipients C) Presence of enteric coating and gastro resistance D) Particle size and solubility at gastric pH Correct! The dissolution rate in oral dosage forms depends on particle size and solubility at gastric pH. What is the significance of understanding dissolution rate in drug formulation? A) To evaluate the effectiveness of enteric coating on tablets B) To assess bioavailability and absorption rate of the drug C) To identify suitable excipients for tablet manufacturing D) To determine the maximum tolerated concentration (MTC) of the drug Correct! Understanding dissolution rate helps in assessing bioavailability and absorption rate of the drug. What does repeated action indicate for modified release forms? A) Plasma concentrations maintained for extended periods B) Delayed drug release C) Rapid drug release D) Therapeutic dose immediately provided Correct! 'Repeated action' indicates a rapid release of the drug in modified release forms. What characteristic makes tablets coated or formulated to prolong release different from other tablets? A) They should be used with antacids for better efficacy B) They provide immediate therapeutic dose C) They have a higher amount of API than standard dosage forms D) They are more suitable for breaking or crushing Correct! Tablets coated or formulated to prolong release contain a higher amount of the active pharmaceutical ingredient (API) than standard dosage forms. What is the primary function of suffixes such as XL (once daily dosing) for prolonged release preparations? A) To enhance rapid drug absorption B) To reduce dosing frequency by providing once daily dosing C) To indicate targeted drug delivery D) To maintain constant plasma concentrations over time Correct! Suffixes such as XL (once daily dosing) for prolonged release preparations serve to reduce dosing frequency by providing once daily dosing. Liquid Oral dosage forms Pharmaceutical suspensions can be solutions, suspensions, emulsions, syrups, or elixirs. Suspensions mix solid particles with liquids, while emulsions involve one liquid in another. Syrups contain sucrose or sugar for convenience, while elixirs contain alcohol. Liquid dosage forms offer rapid absorption and flexible dosing for easier administration. Suspensions are used to administer drugs, including oral, topical, parenteral, and ophthalmic suspensions. Oral suspensions contain flavouring and sweetening compounds to mask bitter taste, while topical suspensions are applied on external surfaces and must be sterile. Ophthalmic suspensions are used to treat eye disorders. Suspensions are suitable for people with difficulty swallowing tablets, have quicker absorption rates, can be used for drugs with low solubility, and can be prepared in powder form. Pharmaceutical suspensions are formed by selecting excipients based on the active pharmaceutical ingredients (API) and the delivery form. Core ingredients include active ingredients, suspending agents, solvents, buffers, anti-foaming agents, flocculating agents, preservatives, antioxidants, colouring agents, flavouring agents, and sweetening agents. Extemporaneous compounding is necessary for treating patients unable to obtain commercially produced medications. The rectal route is an alternative to oral delivery of an API, particularly useful when patients cannot swallow or avoid local adverse reactions. It involves the formation of Rectal Substances or an enema (an injection of fluid into the lower bowel by way of the rectum, which dissolves the API in a solution and infused into the rectum. Parenteral routes include intravascular, intramuscular, subcutaneous, transdermal, and inhalation, with some disadvantages including poor adherence and local irritation. Intravascular/Intramuscular routes allow for precise, accurate, and rapid delivery of APIs. These routes use sterile, pyrogen-free, and isotonic solutions, emulsions, or suspensions admistered using a hypodermic needle. Transdermal delivery involves drug absorption through the skin, with transdermal patches designed for controlled delivery into the systemic circulation. Inhalation therapy delivers APIs to the lungs for local effects or systemic effects, typically using nebulizers, pressurised Metered Dose Inhalers, or Dry Powder Inhalers. These methods ensure controlled drug delivery into the systemic circulation. What is necessary for treating patients unable to obtain commercially produced medications? A) Extemporaneous compounding B) Use of emulsions instead of suspensions C) Additional buffering agents D) Increased alcohol content Correct! The text mentions that extemporaneous compounding is necessary for treating patients unable to obtain commercially produced medications. Chemical Kinetics. Chemical kinetics is the study of chemical reaction rates, which helps understand mechanisms and determine drug stability under different conditions. It is crucial in stability testing, determining the quality of a drug over time, and determining shelf-life. The rate of change is defined as the change in concentration time for change to occur, with a negative sign indicating a positive quantity. Rate = change in concentration / time for change to occur = Rate= [R]t-[R]0/ t At time t=0, the concentration of R is [R]0. Later, at time t, the concentration of R decreases to [R]t. So, to get a positive answer, a minus sign is represented before the [R]t. Leave page 33- 38. And 40-46 https://chemrevise.files.wordpress.com/2017/02/1-9-revision-guide-rateequations.pdf Difference Between Shelf Life and Expiration Date of a Medication: The term "shelf life" refers to a drug's quality over a specified period, while the "expiration date" relates to both quality and safety at a specific point in time. Shelf life is influenced by storage conditions and is usually shortened if not stored in its original container. The expiration date guarantees the full potency and safety of a drug, and it is generally not advisable to use a drug beyond its expiration date unless directed by a pharmacist. Factors accelerating drug decomposition include pH, temperature, chemical reactions, light, and moisture. Store drugs in buffered environments, avoid UV light, and use antioxidants to minimize degradation. Proper packaging and excipients can also help prevent moisture content from increasing drug decomposition rates. Packaging Science Packaging has long been considered low-profile and invisible to the general public, but with increasing environmental awareness, it has become more important. Pharmaceutical packaging, for example, requires more testing than other products, making it an economical means of providing presentation, protection, and identification for a product until it is used or administered. An ideal drug pack should protect the drug, be easy to use, suitable for the target population, carry relevant information, and be aesthetic to increase patient confidence. Primary packaging, such as bottles, caps, and liners, is essential for stability. Secondary packaging adds extra physical protection to primary packs, while tertiary packaging involves bulk transportation in cartons from the warehouse. The pack and package play a crucial role in pharmaceutical products, providing protection, information, accurate dosing, and ensuring supply chain integrity. They protect the product from light, oxygen, bacteria, and moisture, enable accurate dosing, and ensure the product's shelf-life, making them an integral part of the medicine. Packaging is crucial for protecting products from various hazards. Mechanical hazards include shock, vibration, and puncture. Environmental hazards include moisture, temperature, pressure, light, and atmospheric gases. Moisture can cause physical changes, chemical changes, and contamination. The construction of packaging material and quality of stoppers/seals must control water rate to prevent moisture ingress. Temperature can accelerate reactions, while pressure can cause problems in air transport. Light can cause photochemical changes, and atmospheric gases can cause oxidative degradation and pH shifts. Proper packaging construction and quality control are essential for product stability and safety. Permeation of a product can lead to the loss of volatile ingredients, biological hazards, and chemical hazards. Microbiological hazards include yeast contamination, infestations, and human interference. Chemical hazards include the compatibility between the pack and the product, such as the migration and dissolution of components, moisture migration, adsorption of preservatives, and adsorption of volatile components. Anti-tamper seals are developed to address these issues. Pharmaceutical packaging materials include glass, metal, plastic, paper/card, and paper/card. Glass has a successful history due to its inertness, ease of closure, and easy cleaning. Metals have seen a reduction in use due to their sophistication and customization. Aluminium is the preferred metal for packaging, used in collapsible tubes, foils, blister packs, and tamper evident closures. Plastics, such as Polyethylene, PVC, and Polypropylene, are the major primary packaging materials. They are flexible, low in density, lightweight, and costeffective. However, they are not as chemically inert as glass, may contain additives, interact with drug components, and can be permeable to moisture, oxygen, and CO2. Paper/cards are used as secondary packaging for better stacking, display, information carrying, and physical protection. Adherence to medical advice is crucial for effective therapy and reducing NHS resources. Non-adherence can be caused by various factors, including lack of understanding, ineffective management, disease-related factors, physical limitations, and drug-related issues. Packaging type significantly influences adherence, with child-resistant closures being the most common. Restricted access to medicines can lead to reduced adherence, so some patients try to overcome this by using knives, tin openers, intentionally leaving containers open, transferring medication to other containers, or asking children to open them. Packaging can be designed to aid adherence, such as making it easy to access medicines, using devices for physical limitations, memory aids like Monitored Dosage Systems, and calendar packs. Blister packs, while easy to identify, can break tablets and cause swallowing issues. Which environmental hazard can cause physical changes, chemical changes, and contamination to pharmaceutical products? A) Moisture B) Light C) Pressure D) Atmospheric gases Correct! Moisture can cause physical changes, chemical changes, and contamination to pharmaceutical products. What is the main reason behind the reduction in the use of metals as packaging material? A) Low density B) Sophistication and customization C) Flexibility D) Inertness Correct! Metals have seen a reduction in use due to their sophistication and customization. What is the purpose of developing anti-tamper seals for pharmaceutical packaging materials? A) To address leakage issues during air transport B) To prevent atmospheric gases C) To control moisture ingress D) To ensure product stability and safety Correct! Anti-tamper seals are developed to ensure product stability and safety. Why is understanding bulk density essential for tablet formulation? A) To provide aesthetic appeal to the tablet B) To prevent contamination and physical changes in the tablet C) To ensure accurate dosing of the tablet D) To evaluate the flow properties of the tablet powder Correct! Understanding bulk density is essential for tablet formulation to evaluate the flow properties of the tablet powder. What is the significance of understanding dissolution rate in drug formulation? A) To ensure accurate dosing of the medication B) To predict medication adherence C) To ensure the product's shelf-life D) To prolong the release of the medication Correct! Understanding dissolution rate is significant in drug formulation to control and prolong the release of the medication. What is the preferred metal for packaging in pharmaceuticals? A) Aluminium B) Titanium C) Steel D) Copper Correct! Aluminium is the preferred metal for packaging, used in collapsible tubes, foils, blister packs, and tamper evident closures. Which of the following is a disadvantage of using plastics as primary packaging materials? A) Lightweight B) High cost C) Inertness D) Chemical interaction with drug components Correct! Plastics, such as Polyethylene, PVC, and Polypropylene, are the major primary packaging materials. However, they are not as chemically inert as glass, may contain additives, interact with drug components, and can be permeable to moisture, oxygen, and CO2. What is a potential risk associated with permeation of a pharmaceutical product? A) Biological hazards B) Reduced volatility of ingredients C) Increased drug absorption D) Chemical inertness Correct! Permeation of a product can lead to the loss of volatile ingredients, biological hazards, and chemical hazards. Case study 1: The tablet line is experiencing discolouration issues, which may be due to contaminants, packaging treatment, or the chemical composition of the product. Discolouration is visible but not necessarily functional. Possible causes include contaminants, light, and the use of polymeric materials in packaging. Contaminants can be reviewed and managed through GMP processes, while light can be re-formulated. The use of polymeric materials in packaging has increased the number of chemical substrates capable of migration, potentially causing production reactions like discolouration. Pharmaceutical packaging often requires multiple layer solutions, with the outermost layers being the cosmetic element treated with inks. Quality Assurance (QA), Good Manufacturing Practice (GMP) and Clinical Trials. This topic is crucial for pharmacists as they are responsible for the quality of medicines they supply to patients. Understanding how medicines are designed, developed, produced, tested, and issued for marketing and supply is essential for making informed decisions about off-label or unlicensed products. Regulatory Authorities must approve medicines, providing manufacturers with a Marketing Authorisation (MA) number. This also used to be called PL, product licence. What is a marketing authorization holder? A marketing authorization holder (MAH) is the person or company who is licensed to distribute, sell and commercialize a medical product. European Medicines Agency (EMA) approves products for Europe. Products for the UK market are approved by the Medicines & Healthcare Products Regulatory Agency (MHRA). Marketing in the USA requires prior approval from the US Food & Drug Administration. Competent authorities ensure high-quality, safe, and effective medicines, medical devices, promote safe use, license manufacturing units, and prevent illicit and counterfeit medicine sales and supply. New Drug development involves several stages, including discovery of a new drug moiety, pre-clinical trials, and clinical trials. The UK's heavily regulated medicines, along with foodstuffs, require evidence to satisfy the MHRA/EMA for high quality, safety, and effectiveness. The initial stage involves pre-clinical trials, which assess biological activity and benefit-low-risk ratio. Data from these trials is submitted to the Competent Authority for a clinical trials certificate, allowing human Phase I-III clinical trials. If the evidence is sufficient, the new product is approved and manufactured for commercial sale, giving the company a 12-15-year patent life. However, post-market monitoring of the medicine is ongoing, with the MHRA and EMA holding a "List of Medicines Under Additional Monitoring" for further monitoring. What is the primary purpose of measuring the concentration of a drug in the blood? A) To assess the therapeutic effectiveness and safety of the drug B) To identify the metabolic breakdown products of the drug C) To determine the effect of the drug on the patient's immune system D) To establish the potential toxicity of the drug Correct! Measuring the concentration of a drug in the blood helps assess the therapeutic effectiveness and safety of the drug by determining the appropriate dosage and monitoring for potential adverse effects. What characteristic makes tablets coated or formulated to prolong release different from other tablets? A) They exhibit delayed onset of action B) They are more prone to microbial contamination C) They require higher storage temperatures D) They have a higher risk of physical damage during transportation Correct! Tablets coated or formulated to prolong release are different from other tablets because they exhibit delayed onset of action due to their extended-release properties. What is the purpose of assembling data into a 'Dossier' for a marketing authorization application (MA)? A) To finalize the pricing strategy for the new medicine B) To list potential side effects of the new medicine C) To present evidence for the safety and efficacy of the new product D) To identify potential competitors in the market Correct! The Dossier is assembled to present evidence for the safety and efficacy of the new product as part of the marketing authorization application. What does obtaining a patent for a new medicine allow a company to do? A) Sell the medicine at any price they choose B) Share the manufacturing rights with other companies C) Produce the medicine exclusively for the duration of the patent D) Skip the clinical trials for the approved medicine Correct! Obtaining a patent allows the company to have the sole right to produce that medicine for the duration of the patent, providing market exclusivity. What is the significance of the 'List of Medicines Under Additional Monitoring' maintained by MHRA and EMA? A) It identifies which medicines can be sold without a prescription B) It lists medicines with expired patents C) It identifies medicines that require additional post-market surveillance D) It categorizes medicines based on their production costs Correct! The List of Medicines Under Additional Monitoring helps in identifying medicines that require additional post-market surveillance. What is the primary purpose of the 'Yellow Card Scheme' mentioned in the text? A) To monitor the expiration dates of medicines B) To report potential side effects of any medicine C) To provide patients with discounts on new medicines D) To track the manufacturing locations of medicines Correct! The Yellow Card Scheme allows patients and healthcare professionals to report any potential medicine side effects from any medicine, not just new ones. Why are compatibility studies important in drug development? A) To determine the potential allergenic reactions to the drug B) To assess the financial viability of the drug formulation C) To evaluate the stability and interaction of drug components D) To monitor the environmental impact of drug manufacturing processes Correct! Compatibility studies are important in drug development to evaluate the stability and interaction of drug components, ensuring that the formulation remains effective and safe throughout its shelf life. What is a potential risk associated with permeation of a pharmaceutical product? A) Enhanced pharmacokinetic properties of the drug B) Elevated risk of microbial contamination C) Increased likelihood of adverse drug interactions D) Decreased bioavailability of the drug Correct! Permeation of a pharmaceutical product may pose a potential risk by decreasing the bioavailability of the drug, affecting its therapeutic effectiveness. Generic drugs are not sold as the branded version, but follow the same development process as new drugs, except for pre-clinical testing and clinical trials. They must have the same active ingredients, quality, and stability as the branded drug, and have the same therapeutic effect as the brand-name drug. Generic drugs are less expensive than branded drugs due to the innovator's intensive research and expensive development and clinical trials. Paediatric medicines are more difficult to develop due to the uncertainty of long-term effects. The European Medicines Agency (EMA) offers incentives to encourage manufacturers to develop more paediatric medicines, as 90% of medicines given to children are only licensed for adults. Orphan drugs are developed to treat rare diseases, offering benefits such as trial protocol development assistance, scientific advice, market exclusivity, and fee reductions. In what instances might patients be prescribed branded anti-epileptic medicines instead of generic ones? A) When generic medicines are not available in the market B) When branded medicines are significantly cheaper than generic ones C) When the patient cannot be switched between branded and generic medicines D) When branded medicines work better for non-epileptic conditions Correct! There are rare instances where patients must only be prescribed brand (or generic) antiepileptic medicines, and they cannot be switched between the two. Why is it more difficult to undertake clinical trials for paediatric medicines? A) Because 90% of paediatric medicines are licensed for adults B) Because the EMA provides no incentives for paediatric medicine development C) Because paediatric medicines are not considered a priority by manufacturers D) Due to the unpredictable long-term effects of new substances in a growing body Correct! It is more difficult to undertake clinical trials for paediatric medicines as the long-term effects of new substances used in a growing body cannot always be predicted. Why do 90% of the medicines given to children lack sufficient testing for efficacy and safety? A) There is a lack of funding for paediatric medicine research and trials B) Manufacturers prioritize adult medicine development over paediatric medicines C) They are only licensed for adults and not specifically tested in children D) EMA regulations do not require extensive testing for paediatric medicines Correct! Currently 90% of the medicines given to children are only licensed for adults and therefore may not have been sufficiently tested to ensure their efficacy or safety in children. Quality assurance QA: Quality assurance (QA) is a comprehensive approach to ensuring the quality of pharmaceutical products, including Good Manufacturing Practice (GMP) and product design and development. Previously, the UK's MHRA oversees pharmaceutical development and QA, but the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) has collaborated to create a single global quality standard. The ICH has developed guidelines for drug development, which are often incorporated into UK regulations. A Pharmaceutical Quality System (PQS) has been pushed by ICH and is now incorporated into UK regulations, incorporating Quality Risk Management (QRM) and Quality Control (QC). What is the primary focus of Quality Risk Management (QRM) within a Pharmaceutical Quality System (PQS)? A) Facilitating international trade of pharmaceutical products B) Managing the production costs of medicinal products C) Ensuring compliance with environmental regulations D) Identifying and controlling hazards that may affect the quality of the product Correct! Quality Risk Management (QRM) aims to identify and control the hazards that may affect the quality of the pharmaceutical product, ensuring its safety and efficacy. What is a key requirement of a Pharmaceutical Quality System (PQS) in relation to the development of medicinal products? A) Continuous improvement and development throughout the product's life cycle B) Rapid production and distribution upon receiving Marketing Authorization (MA) C) Minimal investment in research and development D) Strict adherence to manufacturing process timelines Correct! A robust PQS requires medicinal products to be continually improved and developed throughout their life cycle, rather than just upon receiving Marketing Authorization (MA), reflecting a new concept in pharmaceutical manufacturing. Which organization published a vision in 2003 to create single, harmonized global quality standards based on good science and risk management principles? A) Good Manufacturing Practice (GMP) B) The Medicines and Healthcare products Regulatory Agency (MHRA) C) The European Medicines Agency (EMA) D) The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Correct! The ICH published a vision in 2003 to create single, harmonized global quality standards based on good science and risk management principles What is the main purpose of the 'The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use' (ICH)? A) To oversee regulatory authority in the pharmaceutical development market B) To create single, harmonized global quality standards based on good science and risk management principles C) To develop pharmaceutical products of the quality required for their intended use D) To produce guidelines about drug development for worldwide implementation Correct! The main purpose of ICH is to create single, harmonized global quality standards based on good science and risk management principles. What is the primary responsibility of the 'The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use' (ICH) in relation to worldwide pharmaceutical development? A) Overseeing regulatory authority in the pharmaceutical development market B) Producing guidelines about drug development and influencing regulatory authorities C) Creating single, harmonized global quality standards based on good science D) Ensuring the quality required for the intended use of pharmaceutical products Correct! The ICH produces guidelines about drug development and influences regulatory authorities in worldwide pharmaceutical development. What is the difference between Quality Assurance (QA) and Quality Control (QC) in pharmaceutical products? A) QA oversees regulatory authority while QC creates global quality standards B) QA focuses on risk management principles while QC ensures the flexibility of primary packaging materials C) QA produces guidelines about drug development while QC ensures product design and development D) QA ensures the quality required for intended use while QC focuses on product inspection and testing Correct! QA ensures the quality required for intended use, while QC focuses on product inspection and testing. Good Manufacturing Practice (GMP) is a part of quality assurance in the pharmaceutical industry, ensuring consistent production and control of products to meet quality standards. The Medicines Act 1968 was the key legislation but has been replaced by the Human Medicines Regulations 2012. The first 'Guide to Good Pharmaceutical Manufacturing Practice' appeared in 1971, following the 1968 Act. It aimed to control quality during manufacture and assembly, with a focus on safety aspects. Although manufacturing has improved over the last 50 years, incidents still occur due to poor GMP. GMP aims to enhance product quality by controlling it from design to production, ensuring it meets requirements through tangible features like shape and appearance, and less tangible characteristics like shelf life, ensuring a high-quality product. A satisfactory Quality Assurance system relies on qualified personnel, clear understanding of individual responsibilities, and awareness of GMP principles. Personnel should receive initial and continuing training relevant to their needs. Premises and equipment must be built and maintained to suit operations, with layouts and designs aiming to minimize errors and allow effective cleaning and maintenance. Standard Operating Procedures (SOPs) are essential for defining, checking, and investigating problems. Documentation is necessary to prevent errors from spoken communication and ensure clarity, conciseness, and regular review. Production activities should follow clearly defined procedures and be performed only by trained and competent people. Deviations from instructions or procedures should be avoided, but changes may be approved in writing by a competent person with the involvement of the Quality Control Department. Validation studies should be conducted to demonstrate that processes lead to expected results. Products and materials should be protected from contamination and stored under appropriate conditions. Quality Control measures actual quality performance compares it with a standard and acts if there are any differences. The responsibility for QC should be held by someone independent from production, and the Quality Control Manager (qualified person) has the decision to release raw materials, intermediate products, and final batches for sale. Analytical methods used by QC personnel must be validated. Complaints and product recalls should be reviewed carefully according to written procedures, and the person responsible for QC should be involved in the study of product defects. Written recall procedures should be regularly checked and updated and recall operations should be initiated promptly and at any time. Internal audits should be conducted independently and detailed by designated competent persons. GMP applies to all individuals working in areas where it applies, including managers, supervisors, and staff. It affects those indirectly involved in activities like maintenance, cleaning, record keeping, and quality and personnel departments. Basic rules of GMP include having correct written instructions, following instructions precisely, using correct equipment and materials, being vigilant for errors, maintaining cleanliness, reporting mistakes, and keeping accurate records. Quality depends on people, and while processes are becoming more automated, many activities still require constant staff care. Dispose of unwanted waste: Pharmacies are required to dispose of unwanted medicines safely, following laws and regulations. Hazardous waste, including explosive, oxidizing, flammable, irritant, harmful, toxic, carcinogenic, corrosive, infectious, toxic for reproduction, mutagenic, sensitizing, ecotoxic, and potentially yielding another substance, is crucial for pharmacists to manage risks and ensure safe disposal. Pharmaceutical waste must be rendered safe by using methods that destroy the component chemicals of chemical or medicinal waste. This is done at specialist waste management sites, not at pharmacies or by pharmacists. Methods include incineration, pyrolysis, plasma technology, and gasification. Incineration involves high temperature heating of waste in the absence of oxygen to produce a synthesis gas, which is mixed with air and combusted in a secondary chamber. Pyrolysis produces a synthesis gas that can be cleaned and combusted in an engine but is avoided for clinical waste due to security of destruction. Plasma technology uses an electric current to produce a plasma with a temperature as high as 6000°C, which destroys pathogenic microbes and converts waste into a glassy rock or slag, ferrous metal, and a synthesis gas. Gasification involves introducing small amounts of air to the primary treatment chamber, raising the temperature and producing ash instead of char. Life cycle of a medicine This involves: • Discovery of a drug • Manufacture of the drug • Formulation of the drug into a medicine • Packaging and distribution of the medicine • Administration of the medicine to or by patients • Excretion of drug and/or metabolites via urine and/or faeces • Disposal of drug and/or metabolites via sewage system • Disposal (or possible recycling) of unused or expired medicines Environmental impact of drug manufacture The 'E factor' measures the amount of waste produced for each kg of drug produced. Pharmaceuticals often have high E factors due to solvents, chemicals, and hazardous chemicals. Herbal drugs have a low E factor but still have environmental impacts due to pesticides, energy, packaging, and transport. Many herbal drugs are collected from the wild, making them scarce and potentially extinct. Fate of a medicine Drugs and their metabolites are excreted in urine and faces after administration, which poses a challenge for waste processing plants and can be toxic to various life forms and humans. The development of antibiotic-resistant bacteria may be encouraged by the presence of small amounts of antibiotics in the environment. In the USA, about 35% of unused medicines are flushed down the toilet. Examples include contamination of river water with oestrogens, and antidepressants like Prozac. More than 50% of antibiotic amoxicillin is excreted unchanged into the environment, increasing the risk of amoxicillinresistant bacteria developing. Diclofenac, a widely used anti-inflammatory drug, has been investigated for its environmental effects after excretion from patients. Sewage treatment plants have reported efficiencies ranging from 0-75%, allowing diclofenac to reach the environment via water leaving the treatment plant. Studies have shown that diclofenac decomposes, particularly in the presence of sunlight, and its decomposition products are 5-6 times more phytotoxic than the parent drug. The 'circular' economy can help minimize the environmental impact of medicines by designing products that can be easily recycled and conserve materials used in their manufacture. The circular economy focuses on designing products that can be easily recycled, reducing environmental impact and conserving materials. This approach is particularly important in medicine, where drugs should be environmentally friendly and not produce toxic metabolites or degradation products. Light-sensitive molecular triggers could be designed into drug molecules to decompose into non-toxic molecules. In Europe, pharmaceutical companies must follow guidelines to assess environmental risks of new drugs. In Sweden, a government-sponsored database has been created to consider biodegradability, bioaccumulation, and toxicity of drugs. Improving compliance and adherence is crucial. Pharmaceutical company GSK has launched an inhaler recycling scheme in partnership with the Co-operative pharmacy. The scheme involves processing used or unwanted inhalers to recover unused propellant and other materials, including plastics, which are then recycled. The propellant used in inhalers is a greenhouse gas, contributing to global warming by forming a "blanket" around the earth. With over 5 million UK patients prescribed inhalers, this scheme has the potential to have significant environmental benefits. Sustainability in Pharmaceuticals: The pharmaceutical industry, a crucial part of healthcare, has a significant environmental impact. To maintain sustainability, the industry must reduce waste, use renewable energy, and improve production processes. Sustainable manufacturing practices, such as using renewable energy, reducing water usage, and optimizing production processes, are being adopted. Additionally, companies are exploring alternative transportation methods like electric or hybrid vehicles to reduce emissions. This will ensure the safety and effectiveness of pharmaceutical products. The pharmaceutical industry is implementing various sustainability initiatives to reduce waste, conserve water, and reduce their carbon footprint. Companies are implementing sustainable packaging solutions, using recyclable materials, and reducing packaging size. For instance, Abbott's Freestyle Libre 3 sensor reduced its total volume by over 70%, reducing plastic use and carton paper. Green chemistry is being explored to minimize hazardous chemicals and waste during manufacturing. Water conservation is another priority, with companies using water-efficient equipment, recycling, and treating wastewater for reuse. Some are also investing in technologies that allow them to use seawater or brackish water in manufacturing processes. Renewable energy sources like solar, wind, and geothermal are being used to power facilities and heat and cool buildings. Promoting sustainability can differentiate the industry from competitors and appeal to environmentally conscious customers. This can be achieved through highlighting commitment to sustainability on websites, marketing materials, and customer communications. Supply chain management involves the interconnection of organizations that produce value to customers through products and services. This is particularly important in the pharmaceutical supply chain, where key stakeholders are manufacturing and closer to the patient. Understanding the linkages and interdependencies is crucial for patient safety and treatment. Supply chains are like human networks, but less sophisticated. The pharmaceutical supply chain faces planning, manufacturing, supply, and logistics issues, with the complexity of temperature control, transit conditions, and security. Globalisation has increased competition and reduced prices, but also opened the door to disruptions like natural disasters, trading changes, and product shortages. The NHS (UK) must manage these challenges. Antimicrobials, including antibiotics, antivirals, and antifungals, are crucial medicines used to prevent and treat infectious diseases in humans, animals, and plants. Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, and parasites no longer respond to these medicines, making them ineffective and increasing the risk of disease spread. Antimicrobial stewardship (AMS) is an organizational or healthcare system-wide approach to promoting and monitoring the judicious use of antimicrobials to preserve their future effectiveness. Topics for AMS teaching include infection prevention and control, antimicrobials and resistance, antimicrobial prescribing and stewardship, vaccine uptake, person-centred care, and interprofessional collaborative practice.
